Clinical Trials Logo

Allergic Conjunctivitis clinical trials

View clinical trials related to Allergic Conjunctivitis.

Filter by:

NCT ID: NCT03489941 Completed - Clinical trials for Allergic Conjunctivitis

A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle

Start date: April 7, 2018
Phase: Phase 3
Study type: Interventional

A Single-Center study to demonstrate the non-inferiority of EM-100 to Zaditor® in the treatment of ocular itching.

NCT ID: NCT03479307 Completed - Clinical trials for Allergic Conjunctivitis

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

Start date: April 7, 2018
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.

NCT ID: NCT03368339 Completed - Clinical trials for Allergic Conjunctivitis

Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis

Start date: December 10, 2017
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of PR013 topical ophthalmic drops (0.045% and 0.06%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis using a modified Conjunctival Allergen Challenge Model (Ora-CAC®).

NCT ID: NCT03320434 Completed - Clinical trials for Allergic Conjunctivitis

Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

Start date: October 13, 2017
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.

NCT ID: NCT03231969 Completed - Clinical trials for Allergic Conjunctivitis

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

Start date: July 20, 2017
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis

NCT ID: NCT03101618 Completed - Asthma Clinical Trials

Animal Allergy in Korean Pet Owners, Pet-related Industry Workers, and Laboratory Animal Reseachers

Start date: August 24, 2016
Phase:
Study type: Observational

The investigators surveyed the prevalence of animal allergy and sensitization to animal allergen among participants in international symposium of Korean association for laboratory science (laboratory animal researchers) and companion animal exhibition (pet owner and pet-related industry workers).

NCT ID: NCT02978183 Completed - Clinical trials for Allergic Conjunctivitis

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

Start date: December 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.

NCT ID: NCT02578914 Completed - Clinical trials for Allergic Conjunctivitis

A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This is a randomized, parallel, single center, double masked, vehicle controlled study. The purpose of this study is to determine the activity and safety of NS2 in patients with grass, tree or ragweed-pollen induced seasonal allergic conjunctivitis . Subjects will be randomized 1:1 to receive multiple doses of NS2 Ophthalmic Drops (0.5%) or NS2 Ophthalmic Drops Vehicle (0.0%). Free aldehydes are thought to be related to inflammatory conditions such as allergic conjunctivitis. NS2, a small molecule aldehyde trap, is being evaluated to determine whether it may decrease inflammation by lowering aldehyde levels.

NCT ID: NCT02322216 Completed - Clinical trials for Allergic Conjunctivitis

Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects

Start date: December 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.

NCT ID: NCT02308501 Completed - Clinical trials for Allergic Conjunctivitis

A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy

Start date: December 2014
Phase: Phase 4
Study type: Interventional

A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft ® as Measured by In-Vivo Confocal Microscopy